^
    2d
    SCALP1: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (clinicaltrials.gov)
    P3, N=703, Completed, Cassiopea SpA | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2026
    Trial completion • Trial completion date
    2d
    The State of Imidazolone as an Evolving Pharmacophore: Current Progress and Clinical Significance in Oncology and AMR. (PubMed, ACS Omega)
    Nevertheless, the significant therapeutic and clinical efficacy of imidazolone-bearing drugs, such as Nilutamide, Irbesartan, and Leucettinib-21, in anticancer, antihypertensive, and neurotherapeutic applications has stimulated increasing interest in imidazolone chemistry and its medicinal potential. The convergence of in silico predictions with experimental findings offers valuable guidance for the rational development of imidazolone-based therapeutics. Overall, this review emphasizes imidazolones as promising scaffolds with significant potential for future drug discovery and development.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2)
    |
    nilutamide
    17d
    Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). (2025-523672-23-00)
    P1/2, N=42, Not yet recruiting, UroTrials GmbH, AIO-Studien gGmbH
    New P1/2 trial
    1m
    PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=692, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Aug 2029 --> Sep 2031
    Trial completion date
    |
    apalutamide • triptorelin • goserelin acetate
    1m
    Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Trial completion date
    1m
    Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study. (PubMed, Cancer Sci)
    This study demonstrated that baseline ctDNA predicts prognosis of Japanese patients with mCSPC receiving apalutamide with ADT and identified potential genetic predictors for treatment-related skin rash. Trial Registration: ClinicalTrials.gov identifier: jRCTs071200040.
    Journal
    |
    AR (Androgen receptor)
    |
    apalutamide
    1m
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Feb 2027 --> Mar 2026
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide
    2ms
    Single center, single-arm, Retrospective study on neoadjuvant Tx of HR LPC with apalutamide (ChiCTR2600121368)
    P=N/A, N=40, THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY; THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY
    New trial
    |
    apalutamide
    2ms
    To evaluate the safety and efficacy of Apololitowereili Monoclonal Antibody combined with FLOT regimen in patients with locally advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma. (ChiCTR2600120362)
    P2, N=29, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • HER-2 negative
    |
    apalutamide
    2ms
    TQB3720-I-01: A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets (clinicaltrials.gov)
    P1, N=192, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=120 --> 192 | Trial completion date: May 2023 --> Dec 2025 | Recruiting --> Terminated; Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial completion date • Trial termination
    |
    TQB3720
    3ms
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide
    3ms
    Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=93, Completed, Institut Paoli-Calmettes | Unknown status --> Completed | N=206 --> 93
    Trial completion • Enrollment change
    |
    apalutamide